MGX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 136667 min ago

@ $12.23

Išleistas: 14 vas. 2024 @ 20:22

Grąža: -42.76%

Ankstesnis signalas: vas. 13 - 21:08

Ankstesnis signalas: Pirkimas

Grąža: 5.43 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States...

Stats
Šios dienos apimtis	52 467.00
Vidutinė apimtis	132 130
Rinkos kapitalizacija	262.25M
Kita pelno data	( $0 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0140 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Novo Holdings A/s	Sell	147 415	SERIES B PREFERRED STOCK
2024-02-08	Novo Holdings A/s	Sell	691 760	SERIES B-1 PREFERRED STOCK
2024-02-08	Noonberg Sarah B.	Sell	0	Common Stock
2024-02-08	Borges Luis	Buy	0

INSIDER POWER
-100.00
Last 3 transactions
Buy: 0 \| Sell: 839 175

Tūris Koreliacija

Ilgas: 0.01 (neutral)

Trumpas: 0.11 (neutral)

Signal:(52.84) Neutral

Metagenomi, Inc. Common Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Metagenomi, Inc. Common Koreliacija - Valiuta/Žaliavos

0.42
( neutral )

-0.28
( neutral )

0.00
( neutral )

0.18
( neutral )

0.30
( neutral )

Financial Reports:

No articles found.

Metagenomi, Inc. Common Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Metagenomi, Inc. Common

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.